Health Care Industry

Risk evaluation and mitigation strategies (REMS): Building a framework for effective patient counseling on medication risks and benefits

8:45 AM - 4:15 PM EDT

Engaging patients: Building trust and support for safety surveillance

9:00 AM - 3:00 PM EDT

health_care021_16x9

Incorporating continuing education into single-drug REMS: Exploring the challenges and opportunities

Gregory W. Daniel and Mark B. McClellan

Wednesday, May 20, 2015

health360_pharma3

Health policy 101: How the Trans-Pacific Partnership will impact prescription drugs

Tuesday, May 19, 2015

Incorporating continuing education into single-drug REMS: Exploring the challenges and opportunities

9:00 AM - 4:15 PM EDT

health360_pharma1

Event recap: Lessons learned from two years of breakthrough therapy designation

Gregory W. Daniel, Elizabeth Richardson, and Craig Streit

Thursday, May 14, 2015

iStock_000006057413Small

Why legislative proposals to improve drug and device development must look beyond FDA approvals

Gregory W. Daniel, Morgan Romine, and Mark B. McClellan

Tuesday, April 28, 2015

RTR1WOB4

Faster, more efficient innovation through better evidence on real-world safety and effectiveness

Mark B. McClellan, Gregory W. Daniel, Adam Aten, Heather M. Colvin, and Morgan H. Romine

Tuesday, April 28, 2015

Breakthrough therapy designation: Exploring the qualifying criteria

8:45 AM - 4:45 PM EDT

health_meddevice

The medical device tax: A primer

Gregory W. Daniel

Thursday, April 23, 2015